We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Abbott Hits Sandoz With New Niaspan Patent Suit

Law360 (February 18, 2011, 1:43 PM EST) -- Abbott Laboratories has launched another patent infringement suit against Sandoz Inc. in an effort to keep a generic version of blockbuster cholesterol drug Niaspan off the market.

Mary B. Graham of Morris Nichols Arsht & Tunnell LLP lodged the suit on behalf of Abbott and its subsidiary Abbott Respiratory LLC in the U.S. District Court for the District of Delaware on Wednesday, accusing Sandoz of infringing Abbott's U.S. Patent Numbers 6,080,428 and 6,469,035.

The suit follows Sandoz's filing of an amended abbreviated new drug application with...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.